Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 1 · 50%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 1 · 50%

Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 3899 participants
GRADE not reported

Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Evolocumab leads to lower any stroke compared with placebo (high certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.79 [0.65, 0.94]
2 studies · 28531 participants
High